Letrozole: Difference between revisions
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
|notes=A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients. | |notes=A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients. | ||
|links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/) | |links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/) | ||
|category= | |category=Repurposed Drugs | ||
}} | }} | ||
Revision as of 22:06, 26 March 2024
| Property | Information |
|---|---|
| Drug Name | Letrozole |
| FDA Approval | Yes (approved for breast cancer; not specifically approved for brain cancer yet) |
| Used for | Experimental for glioblastoma; approved for hormone receptor-positive breast cancer |
| Clinical Trial Phase | Phase 2 |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Hot flashes, joint pain, nausea, increased risk of osteoporosis, fatigue |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 3 - Under investigation |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2.5 |
| Toxicity Explanation | Not specified |
Notes: A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients.
Links: [University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)
From Ben Williams Book: Not specified
